• Decrease
  • Normal
  • Increase
U.S. Department of Health and Human Services

About FDA

Percentage of regulatory cases referred to OFS that were reviewed within the timeframe given to OFS in the Case Management System (measures time in OFS only) in the month

Dictionary: Timely review of regulatory cases that come from the field is important as it allows FDA to take appropriate regulatory action such as issuance of a warning letter to the regulated industry. This can lead to a timely correction of problems in the industry resulting in a safer food supply.

Information is current as of March 31, 2015.

Fiscal Year - 2015

Skip graphic and jump to text data

TimeTargetPercentage
Oct 2014N/A92
Nov 2014N/A63
Dec 2014N/A70
Jan 2015N/A67
Feb 2014N/A86
Mar 2015N/A82
Apr 2015N/ATBD
May 2015N/ATBD
Jun 2015N/ATBD
Jul 2015N/ATBD
Aug 2015N/ATBD
Sep 2015N/ATBD

FY 2015 YTD: 78%

Total number of regulatory cases referred to OFS that were reviewed within the timeframe given to OFS in the Case Management System (measures time in OFS only) in the month

Fiscal Year - 2015
Skip graphic and jump to text data.

TimeTargetNumber
Oct 2014N/A24
Nov 2014N/A10
Dec 2014N/A14
Jan 2015N/A10
Feb 2014N/A12
Mar 2015N/A14
Apr 2015N/ATBD
May 2015N/ATBD
Jun 2015N/ATBD
Jul 2015N/ATBD
Aug 2015N/ATBD
Sep 2015N/ATBD

FY 2015 YTD: 84

Total number of regulatory cases referred to OFS in the month that are due within the month

Fiscal Year - 2015
Skip graphic and jump to text data.

TimeTargetNumber
Oct 2014N/A26
Nov 2014N/A16
Dec 2014N/A20
Jan 2015N/A15
Feb 2014N/A14
Mar 2015N/A17
Apr 2015N/ATBD
May 2015N/ATBD
Jun 2015N/ATBD
Jul 2015N/ATBD
Aug 2015N/ATBD
Sep 2015N/ATBD

FY 2015 YTD: 108

Glossary

Note: The data provided on this website is produced on an ongoing basis for performance management purposes and is subject to change due to updates of preliminary estimates, corrections, or other reasons. In addition, FDA may change the type or amount of data provided on this website at any time. Information marked as "Completed" may include measures and/or key projects for which activities are ongoing but no longer tracked as part of FDA-TRACK.